Honigman Hires Hogan Lovells FDA Regulatory Partner

Suzanne Levy Friedman joins Honigman's regulatory team in Washington, DC

Feb. 3, 2026 at 10:31am

Got story updates? Submit your updates here. ›

Honigman LLP announced on Tuesday that Suzanne Levy Friedman has joined the firm as a partner in its regulatory department in Washington, DC. Friedman previously worked at Hogan Lovells, where her practice focused on guiding clients through the FDA product approval and compliance process, particularly for medical devices, digital health products, and other life sciences technologies.

Why it matters

Friedman's hire is a notable addition to Honigman's regulatory capabilities, as the firm looks to bolster its expertise in navigating the complex and evolving FDA landscape, especially around emerging digital health and software-based products. Her experience will be valuable for Honigman's clients in the life sciences industry.

The details

At Honigman, Friedman will continue her work preparing regulatory submissions for new device clearance and approval, advising on lawful product promotion, and evaluating post-market modifications. She also has expertise in conducting internal investigations related to compliance under the Federal Food, Drug, and Cosmetic Act.

  • Honigman announced Friedman's hire on February 3, 2026.

The players

Suzanne Levy Friedman

A regulatory partner who joined Honigman LLP from Hogan Lovells, where she focused on guiding clients through the FDA approval and compliance process for medical devices, digital health products, and other life sciences technologies.

Honigman LLP

A law firm that has hired Suzanne Levy Friedman as a partner in its regulatory department in Washington, DC, to bolster the firm's expertise in navigating the complex and evolving FDA landscape.

Got photos? Submit your photos here. ›

The takeaway

Honigman's hire of Suzanne Levy Friedman, an experienced FDA regulatory partner, signals the firm's commitment to strengthening its capabilities in the life sciences industry, particularly around emerging digital health and software-based products that require specialized expertise to navigate the shifting regulatory environment.